Equities

Lavipharm SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Lavipharm SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.0742
Data delayed at least 20 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

  • Revenue in EUR (TTM)53.35m
  • Net income in EUR2.95m
  • Incorporated1975
  • Employees208.00
  • Location
    Lavipharm SAAgias Marinas Street, PeaniaPO Box 59ATHINA 190 02GreeceGRC
  • Phone+30 2 106691000
  • Fax+30 2 106642310
  • Websitehttps://www.lavipharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.